BRPI0817108B8 - composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma. - Google Patents

composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.

Info

Publication number
BRPI0817108B8
BRPI0817108B8 BRPI0817108A BRPI0817108A BRPI0817108B8 BR PI0817108 B8 BRPI0817108 B8 BR PI0817108B8 BR PI0817108 A BRPI0817108 A BR PI0817108A BR PI0817108 A BRPI0817108 A BR PI0817108A BR PI0817108 B8 BRPI0817108 B8 BR PI0817108B8
Authority
BR
Brazil
Prior art keywords
composition
kit
fusion protein
chimeric moieties
certain embodiments
Prior art date
Application number
BRPI0817108A
Other languages
English (en)
Portuguese (pt)
Inventor
Xuan Caiyun
L Morrison Sherie
Huang Tzu-Hsuan
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0817108A2 publication Critical patent/BRPI0817108A2/pt
Publication of BRPI0817108B1 publication Critical patent/BRPI0817108B1/pt
Publication of BRPI0817108B8 publication Critical patent/BRPI0817108B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0817108A 2007-09-21 2008-09-19 composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma. BRPI0817108B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99471707P 2007-09-21 2007-09-21
PCT/US2008/077074 WO2009039409A1 (en) 2007-09-21 2008-09-19 Targeted interferon demonstrates potent apoptotic and anti-tumor activities

Publications (3)

Publication Number Publication Date
BRPI0817108A2 BRPI0817108A2 (pt) 2015-03-31
BRPI0817108B1 BRPI0817108B1 (pt) 2020-04-22
BRPI0817108B8 true BRPI0817108B8 (pt) 2021-05-25

Family

ID=40468388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817108A BRPI0817108B8 (pt) 2007-09-21 2008-09-19 composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.

Country Status (12)

Country Link
US (5) US9139634B2 (Direct)
EP (3) EP3150218B1 (Direct)
JP (3) JP5591701B2 (Direct)
KR (2) KR101759460B1 (Direct)
CN (3) CN101868246A (Direct)
AU (1) AU2008302111B2 (Direct)
BR (1) BRPI0817108B8 (Direct)
CA (1) CA2699944C (Direct)
ES (1) ES2536772T3 (Direct)
IL (2) IL204644A (Direct)
MX (2) MX349306B (Direct)
WO (1) WO2009039409A1 (Direct)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013004A (es) 2007-06-01 2010-01-20 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
JP5591701B2 (ja) * 2007-09-21 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
IN2012DN05169A (Direct) * 2009-12-02 2015-10-23 Acceleron Pharma Inc
ES2611479T3 (es) * 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
US20130156765A1 (en) 2010-07-28 2013-06-20 David S. Block FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
DK3604339T3 (da) 2011-01-14 2021-04-12 Univ California Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
US8883982B2 (en) * 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US8961971B2 (en) 2011-12-22 2015-02-24 Development Center For Biotechnology Bispecific T-cell activator antibody
US9492562B2 (en) * 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
EP2822575B1 (en) 2012-03-03 2020-05-06 ImmunGene, Inc. Engineered antibody-interferon mutant fusion molecules
MY174248A (en) * 2012-04-30 2020-04-01 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
HK1210792A1 (en) * 2012-08-20 2016-05-06 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
AU2014249405C1 (en) 2013-03-12 2018-08-16 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2938708T3 (es) 2013-04-29 2023-04-14 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
EP3019531A4 (en) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
ES2757501T3 (es) 2013-07-18 2020-04-29 Vib Vzw Fusocinas que implican citocinas con afinidades de unión al receptor fuertemente reducidas
EP3022226B1 (en) 2013-07-19 2018-12-05 Vib Vzw Targeted modified il-1 family members
JP6475712B2 (ja) 2013-07-19 2019-02-27 ヴィブ ブイゼットダブリュー サイトカインアンタゴニストの標的化
JP6595988B2 (ja) 2013-07-19 2019-10-23 ヴィブ ブイゼットダブリュー ターゲットされる修飾ｔｎｆファミリーメンバー
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
AU2014306322A1 (en) * 2013-08-09 2016-03-17 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with anti-erbB antibody for the treatment of cancers
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
WO2015057834A1 (en) * 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
BR112016012094A2 (pt) 2013-12-04 2017-09-26 Chugai Pharmaceutical Co Ltd moléculas de ligação a antígeno, cuja atividade de ligação a antígeno varia de acordo com a concentração de compostos e bibliotecas das ditas moléculas
EP3139955B1 (en) * 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
EP3221351B1 (en) * 2014-11-19 2024-11-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US20170002057A1 (en) * 2015-02-26 2017-01-05 Nal Pharmaceutical Group Limited Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same
US20210009720A1 (en) * 2015-03-03 2021-01-14 Genopharm Inc. Human interferon-beta variant conjugated immunocytokine and method for preparing same
KR101838919B1 (ko) 2015-03-03 2018-03-15 에이비온 주식회사 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
JP2018516950A (ja) * 2015-06-12 2018-06-28 イミュンジーン, インコーポレイテッドImmunGene, Inc. がん治療のための集中インターフェロン免疫療法
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
JP6452577B2 (ja) * 2015-08-27 2019-01-16 株式会社沖データ 画像形成装置
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
JP6991979B2 (ja) 2016-02-05 2022-03-04 オリオニス バイオサイエンシズ ビーブイ Ｃｄ８結合物質
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
WO2017180764A1 (en) * 2016-04-12 2017-10-19 Immungene, Inc. Focused interferon immunotherapy
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
CA3040343A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
CN110337448B (zh) * 2016-12-23 2023-08-08 瑞美德生物医药科技有限公司 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法
WO2018141964A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
CA3069994A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Pd-1 and pd-l1 binding agents
BR112020002706A2 (pt) 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
WO2019182996A1 (en) * 2018-03-19 2019-09-26 The Regents Of The University Of California Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES
CN112839960B (zh) 2018-08-10 2024-09-06 中外制药株式会社 抗cd137抗原结合分子及其应用
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
JP2022524018A (ja) * 2019-03-06 2022-04-27 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
WO2020198654A1 (en) * 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
AU2020244880A1 (en) 2019-03-28 2021-10-28 Orionfs Biosciences, Inc. Clec9A-based chimeric protein complexes
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
WO2020257412A1 (en) 2019-06-19 2020-12-24 Orionis Biosciences, Inc. Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
KR20210021861A (ko) * 2019-08-19 2021-03-02 (주)제노팜 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
EP4058471A1 (en) * 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
CN119264273A (zh) 2019-12-03 2025-01-07 埃沃特克国际有限责任公司 干扰素相关抗原结合蛋白及其用途
EP4142786A4 (en) * 2020-04-27 2024-06-19 Ohio State Innovation Foundation LIVE ATTENUATED MEASLES VIRUS VACCINE AGAINST SARS-COV-2
IL300062A (en) 2020-07-20 2023-03-01 Deka Biosciences Inc Dual fused cytokine proteins containing IL-10
KR20240045278A (ko) * 2021-08-12 2024-04-05 상하이 티티엠-바이오 테크놀로지 컴퍼니 리미티드 이중특이적 재조합 단백질 및 이의 용도
KR20240015030A (ko) * 2022-07-25 2024-02-02 충남대학교산학협력단 E5의 분비를 위한 재조합 발현 벡터 및 이로 형질전환된약독화 살모넬라 균주
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
AU2024274130A1 (en) 2023-05-12 2026-01-08 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof
WO2025106883A1 (en) * 2023-11-15 2025-05-22 President And Fellows Of Harvard College Engineered fc-prolactin fusions to increase lactation

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
DE3680924D1 (de) 1985-01-14 1991-09-26 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
CZ333796A3 (cs) 1991-03-06 1998-06-17 MERCK Patent Gesellschaft mit beschränkter Haftung Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE69529649T2 (de) 1994-03-17 2003-12-18 Merck Patent Gmbh Anti-egfr einkettige fvs und anti-egfr antikoerper
ES2167391T3 (es) 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
EP0873363B1 (en) * 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
AU706056B2 (en) 1995-10-13 1999-06-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxin containing a disulfide-stabilized antibody fragment
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
EA002474B1 (ru) * 1996-02-20 2002-06-27 Апплайд Резеч Системз Арс Холдинг Н.В. Гибридный белок, образующий гетеродимеры, способ его получения и использования
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
CZ20011049A3 (cs) * 1998-10-05 2002-08-14 Pharmexa A/S Imunogenní kompozice a způsob selekce imunogenního analogu
HK1042098B (zh) * 1998-10-16 2009-10-30 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
CA2379388C (en) * 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
ES2529300T3 (es) * 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
AU6541801A (en) * 2000-06-22 2002-01-02 Idec Pharma Corp Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
ATE437891T1 (de) 2000-12-07 2009-08-15 Lilly Co Eli Glp-1 fusionsproteine
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20070003514A1 (en) 2002-04-05 2007-01-04 The Regents Of The University Of California Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
JP2004093527A (ja) * 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
KR20050107435A (ko) * 2003-02-18 2005-11-11 메르크 파텐트 게엠베하 개선된 특성의 인터페론 알파 뮤테인의 융합 단백질
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
KR20090006221A (ko) * 2004-07-26 2009-01-14 아스테리온 리미티드 연결체들
US20060263368A1 (en) * 2005-01-10 2006-11-23 Research Development Foundation Targeted chimeric molecules for cancer therapy
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
CN101484182B (zh) * 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
JP2008545409A (ja) * 2005-05-26 2008-12-18 シェーリング コーポレイション インターフェロン−ＩｇＧ融合体
US7767799B2 (en) * 2005-06-29 2010-08-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Nucleic acid molecules encoding recombinant interferon-α2 (IFNα2) mutants
NZ542111A (en) * 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay
AU2006302254B2 (en) * 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
KR20080090406A (ko) 2005-11-28 2008-10-08 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
JP5591701B2 (ja) * 2007-09-21 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
US20100047164A1 (en) 2008-04-11 2010-02-25 Duke University Anti-Tumor Antibodies
WO2009134870A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
EP2338055A4 (en) 2008-09-19 2012-10-31 Univ Pittsburgh MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL MAMMARY CARCINOMA
JP2012526079A (ja) 2009-05-06 2012-10-25 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする免疫複合体の使用
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy
US9296811B2 (en) 2010-12-02 2016-03-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for treating a tumor using an antibody that specifically binds HMW-MAA
AU2012215572A1 (en) 2011-02-10 2013-05-02 Roche Glycart Ag Improved immunotherapy
WO2013050725A1 (en) 2011-10-04 2013-04-11 King's College London Ige anti -hmw-maa antibody
EP2822575B1 (en) * 2012-03-03 2020-05-06 ImmunGene, Inc. Engineered antibody-interferon mutant fusion molecules
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy

Also Published As

Publication number Publication date
CN103880965A (zh) 2014-06-25
IL204644A0 (en) 2010-11-30
US20100297076A1 (en) 2010-11-25
KR20160063429A (ko) 2016-06-03
HK1199043A1 (en) 2015-06-19
JP2010540453A (ja) 2010-12-24
CA2699944C (en) 2017-11-14
IL233305A0 (en) 2014-08-31
CA2699944A1 (en) 2009-03-26
ES2536772T3 (es) 2015-05-28
US9534033B2 (en) 2017-01-03
JP2014208701A (ja) 2014-11-06
US20100172868A1 (en) 2010-07-08
CN108129573B (zh) 2021-10-08
JP6087871B2 (ja) 2017-03-01
KR101661770B1 (ko) 2016-10-04
EP3150218A1 (en) 2017-04-05
CN103880965B (zh) 2018-02-16
JP2017031215A (ja) 2017-02-09
US20140079668A1 (en) 2014-03-20
MX349306B (es) 2017-07-19
IL204644A (en) 2014-07-31
BRPI0817108B1 (pt) 2020-04-22
US20110104112A1 (en) 2011-05-05
US8258263B2 (en) 2012-09-04
AU2008302111B2 (en) 2014-04-24
EP2200634B1 (en) 2015-02-11
US8563692B2 (en) 2013-10-22
WO2009039409A1 (en) 2009-03-26
US20170151342A1 (en) 2017-06-01
EP3150218B1 (en) 2021-09-08
CN101868246A (zh) 2010-10-20
KR101759460B1 (ko) 2017-07-18
AU2008302111A1 (en) 2009-03-26
BRPI0817108A2 (pt) 2015-03-31
US10182984B2 (en) 2019-01-22
KR20100084634A (ko) 2010-07-27
MX2010003099A (es) 2010-05-17
EP2853267A1 (en) 2015-04-01
IL233305B (en) 2018-07-31
EP2200634A4 (en) 2012-05-30
US9139634B2 (en) 2015-09-22
JP5591701B2 (ja) 2014-09-17
EP2853267B1 (en) 2016-12-07
CN108129573A (zh) 2018-06-08
EP2200634A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
BRPI0817108B8 (pt) composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
DOP2007000089A (es) Proteínas de fusión rag, formulaciones y métodos de empleos de las mismas
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
CL2011001214A1 (es) Dimero de proteina similar a anticuerpo que comprende un decimo dominio de fibronectina de tipo iii (10fn3) que se une a igf-ir; unido covalentemente o no covalentemente con un 10fn3 que se une a egfr; composicion farmacéutica que lo comprende; uso de dicha composicion para tratar transtornos hiperproliferativo.
CR9186A (es) Composiciones y procedimientos referidos a anticuerpos contra el receptor de igf-1
UY30497A1 (es) Proteinas de fusion comprendiendo una exendina-4, composiciones y aplicaciones
MX2007013759A (es) Agentes de union de esclerostina.
MX338754B (es) Anticuerpos humanos contra el factor tisular.
MX2012003939A (es) Fusiones y conjugados de farmaco.
MX369679B (es) Conjugados de anticuerpo fármaco (adc) que enlazan a proteínas 191p4d12.
CR20120105A (es) Proteínas terapéuticas de unión a dll4
CL2011000117A1 (es) Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende.
CL2012003187A1 (es) Proteinas de union a il-1 beta humana y ala il-1 alfa humana; conjugado de dicha proteina de unión; composicion para la liberacion de una proteina de unión; composicion farmaceutica.
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
CL2011002129A1 (es) Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17.
BRPI0710645A2 (pt) Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
UA115517C2 (uk) Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
CL2011001285A1 (es) Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
DK1791571T3 (da) Radiofluorinerede peptider
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF